Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
C.A. Mason.
Primary care for postproductive women: further thoughts concerning steroid replacement.
Am J Obstet Gy-necol, 170 (1994), pp. 936-966
[2.]
A Oldenhave, LJ Jaszmann, AA Haspels, WT. Everaerd.
Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old.
Am J Obstet Gynecol, 168 (1993), pp. 772-780
[3.]
L. Speroff.
Tratamiento hormonal postmenopáusico. En: Speroff L, Glass RH, Nathan GK, editores. Endocrinología ginecológica e.
infertilidad, pp. 725-781
[4.]
C. Castelo-Branco.
Tratamiento sustitutivo en la menopau-sia.
Revista IberoAmericana de Fertilidad, pp. 30-41
[5.]
C. Castelo-Branco.
Tratamiento hormonal sustitutivo en la.
menopausia. El Farmacéutico-Hospitales, 25 (1991), pp. 43-48
[6.]
C. Castelo-Branco.
Influencia de la THS sobre otras causas de Morbimortalidad.
Libro de Actas del VII Congreso Na-cional de la Asociación Española para el Estudio de la Me-nopausia. Cádiz, pp. 41-46
[7.]
C Castelo-Branco, M Duran, M Puig, JA. Vanrell.
Compliance with hormone replacement therapy at the menopause.
J Obstet Gynaecol, 15 (1995), pp. 204-205
[8.]
C Ritenbaugh, RE Patterson, RT Chlebowski, B Caan, L Fels-Tinker, B Howard, et al.
The Women’s Health Initiative Dietary Modification Trial: overview and baseline characteristics of participants.
Ann Epidemiol, 13 (2003), pp. S87-97
[9.]
J Hsia, JA Simon, F Lin, WB Applegate, MT Vogt, D Hun-ninghake, et al.
Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study.
Circulation, 102 (2000), pp. 2228-2232
[11.]
C. Crandall.
Low dose estrogen therapy for menopausal women: a review of efficacy and safety.
L Womens Health (Larchmt, 12 (2003), pp. 72347
[12.]
Branco C Castelo, F Figueras, A Sanjuán, JJ Vicente, de Osaba MJ Martínez, F Pons, al et.
Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: benefits to bone and analysis of factors associated with discontinuation.
Menopause, 6 (1999), pp. 307-311
[13.]
LA Mattsson, T. Sporrong.
Low dose hormone replacement therapy: clinical efficacy. Minerva.
Ginecol, 55 (2003), pp. 201-207
[14.]
Branco C Castelo, E Casals, C Sanllehy, A Fortuny, JA Vanrell, J. González-Merlo.
Postmenopausal hormone replacement therapy with low dose medroxiprogesterone acetate.Effects on endometrium, plasma lipids, lipoproteins and apolipoproteins.
J Reprod Med, 40 (1995), pp. 305-311
[15.]
JW Nieves, L Komar, F Cosman, R. Lindsay.
Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis.
Am J Clin Nutr, 67 (1998), pp. 18-24
[16.]
KM Prestwood, DL Thompson, AM Kenny, MJ Seibel, CC Pil-beam, LG. Raisz.
Low dose estrogen and calcium have an additive effect on bone resorption in older women.
J ClinEndocrinolMetab, 84 (1999), pp. 17983
[17.]
M Gambacciani, M Ciaponi, B Cappagli, L Piaggesi, AR. Genazzani.
Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal.
women.Maturitas, 28 (1997), pp. 75-81
[18.]
DF Archer, M Dorin, V Lewis, DL Schneider, JH. Pickar.
Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding.
Fertil Steril, 75 (2001), pp. 1080-1087
[19.]
M Gambacciani, M Ciaponi, B Cappagli, AR. Genazzani.
Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopau sal women.
Am J Obstet Gynecol, 185 (2001), pp. 1180-1185
[20.]
JH Pickar, I Yeh, JE Wheeler, MF Cunnane, L. Speroff.
En dometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
Fertil Steril, 76 (2001), pp. 25-31
[21.]
RA Lobo, T Bush, BR Carr, JH. Pickar.
Effects of lower doses of conjugated equine estrogens and medroxyprogester one acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism.
Fertil Steril, 76 (2001), pp. 13-24
[22.]
WH Utian, KA Burry, DF Archer, al et.
and Esclim Study Group. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients.
Am J Obstet Gynecol, 181 (1999), pp. 71-79
[23.]
L Speroff, RW Whitcomb, NJ Kempfert, RA Boyd, JB Paulis-sen, JP. Rowan.
Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms.
ObstetGynecol, 88 (1996), pp. 587-592
[24.]
M Notelovitz, JP Jr Lenihan, M McDermott, IJ Kerber, N Na-navati, J-C. Arce.
Initial 17 B-estradiol dose for treating vasomotor symptoms.
Obstet Gynecol, 95 (2000), pp. 726-731
[25.]
D De Aloysio, LC Rovati, G Giamcovelli, I Setnikar, F. Botti-glioni.
Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study.
Drug Res, 50 (2000), pp. 293-300
[26.]
WH Utian, D Shoupe, G Bachmann, JV Pinkerton, Pickar.
JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and me droxyprogesterone acetate.
Fertil Steril, 75 (2001), pp. 106579
[27.]
LP Shulman, Harari.
D. Low-dose transdermal estradiol for symptomatic perimenopause.
Menopause, 11 (2004), pp. 34-39
[28.]
NN Bhatia, A Bergman, MM. Karram.
Effects of estrogen on urethralfunction in women with urinary incontinence.
Obstet Gynecol, 160 (1989), pp. 176-181
[29.]
GA Greendale, BA Reboussin, P Hogan, VM Barnabei, S Shumaker, S Johnson, et al.
Symptom relief and side effects of postmenopausal hormones: results from the Post-menopausal Estrogen/Progestin Interventions Trial.
Obstet Gynecol, 92 (1998), pp. 982-988
[30.]
F. Kronenberg.
Hot flashes: phenomenology, quality of life, and search for treatment options.
Exp Gerontol, 29 (1994), pp. 319-336
[31.]
L Cardozo, G Bachmann, D McClish, D Fonda, L. Birgerson.
Metaanalysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report ofthe Hormones and Urogenital Therapy Committee.
Obstet Gynecol, 92 (1998), pp. 722-727
[32.]
KE Nilsson, GM. Heimer.
Ultra-low-dose transdermal estrogen therapy in postmenopausal urogenital estrogen deficiency-a placebo-controlled study.
Menopause, 1 (1994), pp. 191-197
[33.]
Consensus Development Conference.
Profilaxis and treatment of osteoporosis.
Am J Med, 90 (1991), pp. 107-110
[34.]
B Ettinger, HK Genant, CE. Cann.
Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium.
Ann Intern Med, 106 (1987), pp. 40-45
[35.]
H Mizunuma, H Okano, M Soda, et al.
Prevention of post-menopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study.
Maturitas, 27 (1997), pp. 69-76
[36.]
SF Evans, MW. Davie.
Low and conventional clase trans-dermal oestradiol are equally effective at preventing boDe loss in spine and femur at all post menopausal ages.
Clin Endocrinol, 44 (1996), pp. 79-84
[37.]
RR Recker, KM Davies, RM Dowd, RP. Heaney.
The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderIy women. A randomized, controlled trial.
Ann Intern Med, 130 (1999), pp. 897-904
[38.]
M Gambacciani, M Ciaponi, B Cappagli, AR. Genazzani.
Effects of low-dose continuous-combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopau-sal.
women. Am J Obstet Gynecol, 185 (2001), pp. 1180-1185
[39.]
P. Markers Garnero.
of bone turnover for the prediction of fracture risk.
Osteoporosis Int, 11 (2000), pp. 555-565
[40.]
PD Ross, JW Davis, RS Epstein, RD. Wasnich.
Pre existing fractures and bone mass predict vertebral fracture incidence in women.
Ann Intern Med, 114 (1991), pp. 919-923
[41.]
LJ III Melton, EJ Atkinson, WM O’Fallon, HW Wahner, BL. Riggs.
Long-term fracture predicrion by bone mineral assessed at different skeletal sites.
J Bone Miner Res, 8 (1993), pp. 1227-1233
[42.]
C Castelo-Branco, E Casals, C Sanllehy, A Fortuny, JA Vanrell, J. González-Merlo.
Postmenopausal hormone replacement therapy with low-dose medroxiprogesterone acetate.Effects on endometrium, plasma lipids, lipoproteins and apolipoproteins.
J Reprod Med, 40 (1995), pp. 305-311
[43.]
KL Cushing, NS Weiss, LF Voigt, B McKnight, SA. Beresford.
Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens.
Obstet Gynecol, 91 (1998), pp. 35-39
[44.]
E Weiderpass, JA Baron, HO Adami, C Magnusson, A Lind-gren, R, Bergstrom, et al.
Low-potency oestrogen and risk of endometrial cancer: a case-control study.
Lancet, 353 (1999), pp. 1824-1828
[45.]
WB Kannel, MC Hjortland, PM McNamara, T. Gordon.
Menopause and risk of cardiovascular disease. The Framing-ham Study.
Ann Intem Med, 85 (1976), pp. 447-452
[46.]
WB. Kannel.
Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study.
Am Heart J, 114 (1987), pp. 413-419
[47.]
Group for the PEPI Trial. Writing.
Effects of estrogen or estrogenl progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial.
JAMA, 273 (1995), pp. 199-208
[48.]
RA Lobo, JH Pickar, RA Wild, B Walsh, E. Hirvonen.
Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women.
Obstet Gynecol, 84 (1994), pp. 987-995
[49.]
H Luotola, T Pyörälä, M. Loikkanen.
Effects of natural oes-trogenl/progestogen substitution therapy on carbohydrate and lipid metabolism in postmenopausal women.
Maturitas, 8 (1986), pp. 245-253
[50.]
W Schlegel, LI Petersdorf, R Junker, H Schulte, Ebert.
C, Van Eckardstein A. The effects of six months of treatment with a low-dose of conjugated oestrogens in menopausal women.
Clin Endocrinol (Oxf, 51 (1999), pp. 643-651
[51.]
HK Genant, J Lucas, S Weiss, M Akin, R Emkey, H Mc-Nancy-Flint, et al.
Low dose esterified estrogen therapy. Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels.
Arch Intem Med, 157 (1997), pp. 2609-2615
[52.]
K.K. Koh, M.K.I. Home, R.O.L. Cannon.
Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postrnenopausal women.
Thromb Haemost, 82 (1999), pp. 626-633
[53.]
L. Mosca.
The role of hormone replacement therapy in the prevention of postmenopausal heart disease.
Arch Intem Med, 160 (2000), pp. 2263-2272
[54.]
L. Mosca.
Hormone replacement therapy in the prevention and treatment of atherosclerosis.
Curr Atheroscler Rep, 2 (2000), pp. 297-302
[55.]
D.M. Herrington, D.M. Reboussin, K.B. Brosnihan, P.C. Sharp, S.A. Shumaker, T.E. Snyder, et al.
Effects of estrogen replacement on the progression of coronary-artery atherosclerosis.
N Engl J Med, 343 (2000), pp. 522-529
[56.]
S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, et al.
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women.
JAMA, 280 (1998), pp. 605-613
[57.]
E. Hemminki, K. McPherson.
Impact fo postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical.
trials. BMJ, 315 (1997), pp. 149-153
[58.]
G. Mercuro, C. Vitale, M. Fini, S. Zoncu, F. Leonardo, G. Rosano.
Lipid profiles and endotelial function with low-dose hormone replacement therapy in postmenopausal women at risk for coronary artery disease: a randomized trial.
Int J Cardiology, 89 (2003), pp. 257-265
[59.]
P.M. Spritzer, D. Vitola, L.C. Vilodre, M.C. Wender, F.M. Reis, C. Ruschel.
One year follow-up of hormone replacement therapy with percutaneous estradiol and low dose vaginal natural progesterone in women with mild to moderate hypertension.
Exp Clin Endocrinol Diabetes, 111 (2003), pp. 267-273
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
